TLRY — Tilray Brands, Inc.

Tilray Brands (TLRY) Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Revenue: $206.7 million, an 11% increase year-over-year.
• Gross Profit: $55 million, up 6% year-over-year, with a gross margin of 27%.
• Net Loss: $25.2 million, significantly improved from a loss of $793.5 million in the prior year.
• Adjusted EBITDA: $10.7 million, a 19% increase year-over-year.
• Cash Position: $264.8 million in cash, restricted cash, and marketable securities, with a net cash position of $3.5 million.

2. Strategic Updates and Business Highlights:

• International Expansion: Strong growth in international cannabis sales, with a 73% increase year-over-year, driven by significant sales volume growth in medical cannabis.
• Beverage Business: Acquired BrewDog, enhancing Tilray's position in the craft beverage market, and entered a partnership with Carlsberg to expand distribution in the U.S.
• Distribution Growth: CC Pharma recognized as a top innovator in the European pharmaceutical market, contributing to a 35% year-over-year increase in distribution revenue.
• Product Innovation: Launched new cannabis strains and expanded wellness product offerings, achieving a 16% increase in wellness revenue.

3. Forward Guidance and Outlook:

• Adjusted EBITDA Guidance: Reaffirmed guidance for fiscal 2026 at $62 million to $72 million.
• Growth Expectations: Anticipated continued momentum in international markets and improvements in beverage margins as integration efforts progress.

4. Bad News, Challenges, or Points of Concern:

• Price Compression: Experienced $7 million in price pressure in international markets, impacting margins.
• Operational Challenges: Integration of BrewDog and ongoing adjustments in the beverage segment may present challenges.
• Regulatory Environment: Ongoing uncertainty regarding U.S. cannabis regulations and potential impacts on hemp-derived THC products.
• Rising Costs: Increased aluminum and input costs affecting beverage margins, with the potential for further cost pressures from fuel surcharges.

5. Notable Q&A Insights:

• Balancing International and Canadian Markets: Management emphasized the importance of maintaining supply for international markets while stabilizing Canadian operations, highlighting increased cultivation capacity.
• Project 420 Completion: Management indicated that while Project 420 has concluded, ongoing cost-saving initiatives will continue as part of normal operations.
• Route to Market in Germany: Discussion on the importance of vertical integration and the role of CC Pharma in expanding pharmacy reach and improving margins.
• Beverage Segment Margins: Management indicated that Q3 margins represent a trough, with expectations for improvement as operational efficiencies are realized and new partnerships take effect.
• BrewDog Integration: Management acknowledged the challenges of stabilizing BrewDog's operations post-acquisition but expressed optimism about the brand's potential and integration synergies.

This summary encapsulates Tilray's financial performance, strategic initiatives, and outlook while addressing challenges and insights from the Q&A session, providing a balanced view of the company's current status and future direction.